Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPreventive Services & ScreeningAetna DTaP/Tdap/Td Coverage Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0653

    Diphtheria, Tetanus, and Pertussis Vaccines

    Customize your policy alerts

    Sign up for Aetna Policy 0653 alerts

    Get alerted when Policy 0653 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity coverage for diphtheria, tetanus, and pertussis vaccines, including specific combination products, booster doses, wound management indications, and adherence to ACIP recommendations; applies to Aetna members (national policy).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyDiphtheria, Tetanus, and Pertussis Vaccines
    Policy CodePolicy 0653
    Change TypeNo material changes
    Effective DateJan 17, 2003
    Last ReviewSep 14, 2023
    Next Review DateJul 11, 2024
    Key ActionAdminister one dose of Tdap to pregnant patients during each pregnancy at 27–36 weeks' gestation; document immunization history and gestational age.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥5 yrsWound management indication
    27–36 wksPregnancy Tdap window
    CPT/ICDCoding included
    5-shotDTaP primary series
    09/14/2023Last review

    Coverage Criteria for Diphtheria, Tetanus, and Pertussis Vaccines

    inv-01: Medically Necessary Vaccines and Indications

    Aetna considers the following vaccines medically necessary:

    Medically necessary vaccines list: 1) Diphtheria, tetanus toxoid, and whole-cell or acellular pertussis vaccines per ACIP preventive recommendations; 2) DTaP-IPV-HepB (Pediarix) as an acceptable alternative for doses at 2, 4, and 6 months of age; 3) DTaP-IPV/Hib (Pentacel) as an acceptable alternative for children 6 weeks through 4 years for a 4-dose series at 2, 4, 6, and 15–18 months; 4) DTaP-IPV (Kinrix) as the fifth DTaP and fourth IPV dose in children 4–6 years with the specified prior vaccine history; 5) DTaP-IPV (Quadracel) as the fifth DTaP and fourth/fifth IPV dose for certain children 4–6 years who received four doses of Pentacel and/or Daptacel; 6) DTaP-IPV-Hib-HepB (Vaxelis) as an acceptable 3-dose alternative at 2, 4, and 6 months for children 6 weeks through 4 years; 7) Boostrix (Tdap) as a single preventive booster for individuals ≥10 years; 8) Adacel (Tdap) as a single preventive booster for individuals 10–64 years (alternative to Td in this age group); 9) Tdap as a single preventive dose for individuals ≥65 years and for pregnant women regardless of prior history (or postpartum if not given during pregnancy); 10) Tdap as a single dose for children 7–10 years with incomplete or unknown pertussis history; 11) A tetanus toxoid–containing immunization (DT, DTaP, Td, or Tdap) for treatment of contaminated wounds; 12) Preservative-free Td (Tenivac) as an acceptable alternative for medically necessary indications.

    Enumerated as distinct covered indications in policy.

    inv-02: Schedule, Catch-up, Pregnancy, and Wound Management Guidance

    ACIP-derived scheduling and catch-up guidance referenced as coverage context:

    Routine childhood schedule: Children <7 years: 5-dose DTaP series with primary doses at 2, 4, and 6 months and booster doses at 15–18 months and 4–6 years per ACIP.

    From ACIP routine schedule.

    Catch-up for persons 7–18 years and ≥19 years: If never vaccinated: a 3-dose series of tetanus-diphtheria–containing vaccines that includes at least 1 Tdap; preferred sequence is Tdap first, then Td or Tdap ≥4 weeks later, and a final Td or Tdap dose 6–12 months later.

    Preferred catch-up schedule per ACIP.

    Pregnancy recommendation: Pregnant women should receive 1 dose of Tdap during each pregnancy at 27–36 weeks’ gestation (preferably earlier in the window), regardless of prior Tdap history; Tdap is preferred if a tetanus-containing vaccine is indicated during pregnancy.27-36 weeks gestation preferred

    ACIP recommendation included in policy.

    Wound management indication (coverage context): A tetanus toxoid–containing vaccine is indicated for wound management when >5 years have passed since the last tetanus-containing dose; assess wound type, immunization status and consider TIG for contaminated/dirty wounds.

    inv-03: Indications: Wound management and Pregnancy

    Covered when meeting ACIP/clinical indications described below:

    Wound management tetanus prophylaxis: If >5 years have passed since the last tetanus toxoid–containing vaccine, administer a tetanus toxoid–containing vaccine for wound management; for persons ≥11 years without documented Tdap or with unknown Tdap history, Tdap is preferred; for pregnant women requiring wound management, use Tdap. Assess wound contamination and consider TIG for contaminated/dirty wounds; TIG dose for prophylaxis is 250 IU IM and is indicated for unvaccinated persons, those without a primary series, and persons with severe immunodeficiency.>5 years since last tetanus-containing vaccine

    Includes TIG dosing and indications.

    Pregnancy vaccination indications: Administer 1 dose of Tdap during each pregnancy at 27–36 weeks’ gestation (preferably earlier in the window). If Tdap was not given during pregnancy and the woman has never received prior Tdap, give immediately postpartum. If vaccinated early in pregnancy before 27 weeks, do not repeat during 27–36 weeks.27-36 weeks gestation preferred

    ACOG/ACIP pregnancy guidance.

    inv-04: Vaccine Product Use

    Vaccine-specific administration/use covered statements:

    DT/DTaP series and combination vaccines: DT is for children 6 weeks through 6 years who should not receive pertussis-containing vaccines (5-dose series). DTaP (Infanrix, Daptacel) is a 5-dose series for infants and children 6 weeks through 6 years. Combination vaccines (Pentacel, Pediarix, Kinrix, Quadracel, Vaxelis) have specific FDA-approved age and dose uses to complete primary or booster schedules; follow product-specific approvals for which doses they may substitute or complete, and note limited mixed-sequence data for some combinations.age-specific per product

    Product-specific interchangeability and mixed-sequence data are limited; follow manufacturer guidance.

    Td boosters and use: Td is administered every 10 years as a booster for persons 7 years or older and may be used as part of a 3-dose primary series in persons ≥7 years who have not previously received tetanus/diphtheria vaccines.10 years

    ACIP decennial booster guidance.

    Tdap product-specific use:

    inv-05: Routine maternal Tdap administration

    Covered when ALL of the following are met

    Tdap during each pregnancy: Obstetric care providers should administer Tdap to all pregnant patients during each pregnancy, as early in the 27–36 weeks’ gestation window as possible.27-36 weeks gestation

    If not administered during pregnancy, give immediately postpartum if the woman has never received prior Tdap.

    inv-06: Exceptions and alternative timing

    Covered when ANY of the following indications apply

    Exceptions and alternative timing: Tdap may be administered outside the 27–36 week window for wound management, during a pertussis outbreak, or other extenuating circumstances where immediate protection is needed. If a pregnant woman was vaccinated early in pregnancy (before 27 weeks), she does not need to be revaccinated during 27–36 weeks.n/a

    Policy acknowledges specific scenarios where timing outside the preferred window is appropriate.

    The older whole-cell DTP vaccine has been replaced by acellular pertussis-containing formulations. As noted in the policy background, DTP is no longer recommended and DTaP (acellular pertussis) is preferred for the childhood five-dose primary and booster series because it is associated with fewer side effects. DT remains available only for children 6 weeks through 6 years who should not receive pertussis-containing vaccines.

    The policy therefore specifies coverage for modern acellular pertussis vaccines (DTaP and Tdap) and their approved combination formulations per ACIP/labeling, and indicates that whole-cell DTP is not recommended for routine use.

    Manufacturers’ product information indicates that some combination vaccine interchangeability and mixed-sequence use have limited or no safety/immunogenicity data. For example, Pentacel and Daptacel contain different amounts of pertussis antigens and data are not available on the safety and immunogenicity of mixed Pentacel–Daptacel sequences for successive primary doses. Similarly, Vaxelis labeling states that data are not available on safety or effectiveness when used following 1 or 2 doses of DTaP from a different manufacturer.

    Because these mixed-sequence data are limited, the policy documents caution about extrapolating immunogenicity and safety across manufacturers for successive doses of combination DTaP-containing vaccines and recommends following product-specific guidance when completing primary or booster series.

    Within the extracted policy text there are no explicit exclusions stated for the covered tetanus, diphtheria, and pertussis vaccines. The document focuses on ACIP-recommended indications, timing (including pregnancy), product-specific use, and situations such as wound management rather than listing specific non-covered scenarios.

    The policy emphasizes routine maternal Tdap administration during each pregnancy in the recommended window of 27–36 weeks’ gestation to maximize neonatal passive antibody protection. It notes Tdap is safe in pregnancy and should be given as early in that window as possible.

    Supporting evidence cited in the background indicates that Tdap given pre-conception or in early pregnancy may result in lower pertussis-specific antibody levels in infants compared with third-trimester maternal immunization. Healy et al. (2013) found infants of mothers immunized pre-conception or in early pregnancy had estimated pertussis toxin IgG levels often below assay quantitation by age 2 months, suggesting third-trimester immunization better supports infant antibody levels and underpins the recommendation for vaccination at 27–36 weeks.

    Billing and Diagnosis Codes

    Covered CPT Codes (general DTaP/Tdap administration)CPTCovered
    90471Immunization administration; one vaccine (single or combination vaccine/toxoid).
    90472Each additional vaccine (single or combination vaccine/toxoid).
    90700Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use.
    90715Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use.
    Covered CPT Codes (combination vaccines)CPTCovered
    90696DTaP-IPV (Diphtheria, tetanus toxoids, acellular pertussis and inactivated poliovirus vaccine), when administered to children 4 through 6 years of age, for intramuscular use.
    90697Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use.
    90698Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine (DTaP-IPV/Hib), for intramuscular use.
    90723Diphtheria, tetanus toxoids, and acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use.
    Covered CPT Codes (DT/Td)CPTCovered
    90702Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, intramuscular use.
    90714Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, intramuscular use.
    Covered ICD-10 CodesICD-10Covered
    Z23Encounter for immunization.

    Provider Actions, Billing & Documentation Requirements

    Billing Rule

    Billing codes to use — Immunization administration and vaccine product codes

    Billing: Providers must bill the exact immunization administration and vaccine product CPT/HCPCS codes listed for the covered vaccines. Use 90471 for the first vaccine administration and 90472 for each additional vaccine administered during the same encounter. Use the product-specific CPT/HCPCS codes shown (e.g., 90700, 90702, 90714, 90715, 90696, 90697, 90723 as applicable). Include ICD-10 code Z23 (Encounter for immunization) when documenting routine immunization encounters.

    • Bill immunization administration with 90471 (first vaccine) and 90472 (each additional vaccine).
    • Bill the specific vaccine product CPT/HCPCS code for the vaccine given (examples above).
    • Include ICD-10 Z23 for immunization encounters.
    Prior Authorization

    Background and Rationale

    Vaccines are available to protect against diphtheria, tetanus and pertussis. The policy references the range of licensed products: DT/ Td formulations for diphtheria and tetanus alone; DTaP formulations for the pediatric five-dose series (examples include Daptacel, Infanrix, Pentacel, Pediarix, Quadracel, Vaxelis); and Tdap boosters for older children, adolescents and adults (Adacel, Boostrix).

    ACIP-recommended routine childhood DTaP schedule is described in the policy as primary doses at 2, 4, and 6 months with boosters at 15–18 months and 4–6 years. For adults and adolescents, Tdap is recommended as the booster formulation, and maternal Tdap is recommended during each pregnancy (preferred at 27–36 weeks’ gestation) to protect newborns via transplacental antibody transfer.

    Definitions

    DTaP — definition
    DefinitionDiphtheria, tetanus, and acellular pertussis vaccine (DTaP) contains full-strength diphtheria and pertussis components and provides protection against diphtheria, tetanus, and whooping cough; DTaP replaced whole-cell DTP due to fewer side effects.
    Common productsExamples include Daptacel®, Infanrix®, Kinrix®, Pediarix®, Pentacel®, Quadracel®, and Vaxelis™.
    Indicated age/seriesRecommended by ACIP for the five-dose childhood series (primary doses at 2, 4, and 6 months; boosters at 15–18 months and 4–6 years).
    Tdap / Td / DT — definitions and use
    Tdap (general)Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) — reduced 'd' and 'p' indicate lower-dose diphtheria and pertussis components compared with DTaP.
    Td
    Policy Summary
    PayerAetna
    PolicyDiphtheria, Tetanus, and Pertussis Vaccines
    Policy CodePolicy 0653
    Change TypeNo material changes
    Effective DateJan 17, 2003
    Last ReviewSep 14, 2023
    Next Review DateJul 11, 2024
    Key ActionAdminister one dose of Tdap to pregnant patients during each pregnancy at 27–36 weeks' gestation; document immunization history and gestational age.
    SourceLink
    On This Page
    Coverage Criteria for Diphtheria, Tetanus, and Pertussis VaccinesBilling and Diagnosis CodesProvider Actions, Billing & Documentation RequirementsBackground and RationaleDefinitions
    >5 years since last tetanus-containing vaccine

    Wound management details provided.

    Adacel is approved for persons 10–64 years (includes a 2019 FDA approval for a second dose if ≥8 years after the first and for use for wound management if ≥5 years since prior tetanus-containing vaccine). Boostrix is approved for persons 10 years and older. Tdap may be used in some circumstances as a substitute for Td per ACIP guidance (decennial booster, wound management, catch-up when at least 1 Tdap dose given).
    age indications per product

    Product approvals and 2019 Adacel labeling changes noted.

    Prior authorization — None required

    Prior authorization: No prior authorization requirement is specified for administration of DTaP/Tdap/Td vaccines in this policy. Providers should follow clinical indications and vaccine-preference guidance rather than submit prior authorization.

    • No PA required per this section.
    Documentation Required

    Wound-related coding requirements

    Wound-related coding requirements: When immunization is provided for wound management, include appropriate ICD-10 injury/wound codes documenting the type and location of the wound (example ranges: S00–S99 and selected T-codes as applicable). Also include documentation that supports the clinical indication for tetanus prophylaxis.

    • Use relevant ICD-10 injury codes (e.g., S01.x, S10.x ranges shown in policy) to document the wound.
    • Include supporting diagnosis codes alongside Z23 when immunization is for wound management.
    Documentation Required

    Wound management timing and vaccine preference for wound indications

    Wound management timing: Document that >5 years have elapsed since the last tetanus-toxoid containing vaccine when administering a tetanus toxoid-containing vaccine for wound management. For persons ≥11 years without prior documented Tdap or with unknown Tdap history, Tdap is preferred. For pregnant women requiring tetanus prophylaxis, use Tdap.

    • Confirm and document interval since last tetanus-containing dose (>5 years for wound indication).
    • If patient ≥11 years and Tdap history absent/unknown, preferentially administer Tdap.
    • For pregnant patients requiring tetanus prophylaxis, administer Tdap.
    Note

    No step therapy or additional PA/documentation requirements specified

    Provider actions not otherwise specified in this section: No step therapy requirements or other utilization management (beyond standard coding/documentation) are described in this section. Also, there are no additional documentation or prior authorization requirements specified in the extracted text beyond those listed.

    • No step therapy requirements described.
    • No additional prior authorization or documentation requirements specified here beyond coding and clinical documentation guidance.
    Documentation Required

    Required diagnostic documentation

    Required diagnostic documentation: Document the encounter reason (Z23 for immunization) and, when relevant, the specific wound/injury ICD-10 code(s) supporting wound management (include type and contamination status).

    • Include Z23 for routine immunization encounters.
    • When immunizing for wound management, document the specific wound ICD-10 code(s) (type/location).
    • Document wound contamination status if applicable.
    Documentation Required

    Required documentation — Immunization, wound, and pregnancy details

    Required documentation: Record immunization history (including prior Tdap or tetanus-containing vaccines), date of last tetanus-toxoid containing vaccine, wound type and contamination status for wound-related indications, and gestational timing when vaccinating pregnant patients. For pregnancy, document the gestational age and that Tdap was given ideally at 27–36 weeks’ gestation (or the clinical reason if given outside that window).

    • Immunization history and dates (including prior Tdap).
    • Date of last tetanus-toxoid containing vaccine (to establish >5 years for wound indication).
    • Wound type and contamination status when relevant.
    • Pregnancy: gestational age at vaccination and indication if given outside 27–36 weeks.
    Documentation Required

    Document maternal Tdap administration timing

    Document maternal Tdap administration timing: For pregnant women, document that Tdap was administered at 27–36 weeks’ gestation (preferably earlier in that window). If Tdap was given earlier in pregnancy or postpartum due to extenuating circumstances (wound, outbreak, etc.), document the reason; repeat vaccination during 27–36 weeks is not required if already given during the current pregnancy.

    • Record gestational age/date of Tdap administration.
    • If administered outside 27–36 weeks, document clinical justification (wound management, outbreak, etc.).
    • Do not revaccinate during 27–36 weeks if Tdap already given during the same pregnancy.
    Note

    Vaccine preference guidance — Tdap vs Td and catch-up sequencing

    Vaccine preference guidance: For persons ≥11 years who require a tetanus toxoid-containing vaccine and have no prior Tdap or unknown Tdap history, preferentially use Tdap. For pregnant women, Tdap should be used during each pregnancy (27–36 weeks preferred). For nonpregnant persons with documented prior Tdap, either Td or Tdap may be used when indicated. For catch-up schedules in persons 7–18 years, preferred sequence is Tdap first, then Td or Tdap ≥4 weeks later, then Td or Tdap 6–12 months later.

    • Prefer Tdap for ≥11 years with absent/unknown Tdap history.
    • Administer Tdap to pregnant women during each pregnancy (27–36 weeks preferred).
    • If prior Tdap documented in nonpregnant adults, either Td or Tdap may be used for boosters.
    • Catch-up for 7–18 years: Tdap → Td/Tdap ≥4 weeks → Td/Tdap 6–12 months later.
    Tetanus and diphtheria toxoids (Td) — booster every 10 years for persons 7 years or older; may be used in a 3-shot primary series for persons ≥7 years who have not previously been vaccinated.
    DTDiphtheria and tetanus toxoid (DT) — administered as a 5-shot series to children 6 weeks through 6 years who should not receive pertussis-containing vaccines.
    TIG — definition and wound prophylaxis use
    DefinitionHuman tetanus immune globulin (TIG) provides temporary passive antitoxin immunity by delivering pooled human tetanus antitoxin to neutralize unbound toxin.
    Indication for prophylaxisTIG is indicated for prophylaxis in contaminated/dirty wounds for persons who are unvaccinated or who have not completed a primary series of tetanus toxoid-containing vaccines; also indicated for persons with HIV or severe immunodeficiency who have contaminated wounds, regardless of immunization history.
    Dose and routeRecommended prophylactic dose is 250 IU administered intramuscularly (IM).
    Tdap — examples and use
    Tdap as boosterTdap is used as a single booster dose for adolescents and adults (approved products include Adacel® and Boostrix®).
    Pregnancy useObstetric care providers should administer 1 dose of Tdap during each pregnancy, ideally in the 27–36 weeks' gestation window; if not given during pregnancy, give immediately postpartum if no prior Tdap.
    Product age indicationsAdacel is approved for persons 10–64 years (with 2019 approval allowing a second dose ≥8 years after the first and for wound management when ≥5 years have elapsed); Boostrix is approved for persons 10 years and older.
    Tdap — vaccine description
    RestatementTdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (reduced 'd' and 'p' compared with DTaP).
    RoleUsed as booster immunization and preferred tetanus-containing vaccine for pregnant women and for persons ≥11 years without documented prior Tdap when tetanus vaccination is indicated.
    Interchangeability noteTdap may be used in place of Td in some indications per ACIP guidance (e.g., decennial booster, wound management when timing criteria are met).
    Cocooning — definition
    DefinitionCocooning is the strategy of vaccinating postpartum mothers and other close contacts of newborns (e.g., fathers, grandparents) with Tdap to reduce infant pertussis risk.
    Comparative effectivenessACIP pregnancy vaccination is preferred to postpartum cocooning; modeling found pregnancy vaccination could reduce infant cases by 33% versus 20% for postpartum vaccination, and avert more hospitalizations and deaths at lower cost.
    Policy positionWhile cocooning remains an ACIP recommendation, vaccination during pregnancy provides greater and more cost-effective protection for infants and is the preferred approach.